Revance Therapeutics reported $10.66M in Stock for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Stock Change
Abbvie ABBV:US $ 3483M 355M
ALKERMES ALKS:US $ 154.79M 4.45M
Bristol Myers Squibb BMY:US $ 2104M 9M
Cara Therapeutics CARA:US 1.91M 677K
Eli Lilly And LLY:US $ 3893M 7M
Endo International Ordinary Shares ENDP:US $ 283.83M 0.27M
JAZZ PHA JAZZ:US $ 985.45M 87.27M
Johnson & Johnson JNJ:US $ 10990M 603M
Merk MRK:US $ 5774M 179M
Neurocrine Biosciences NBIX:US $ 29M 1.5M
Pacira Pharmaceuticals PCRX:US $ 103.66M 5.11M
Procter & Gamble PG:US $ 7101M 428M
Revance Therapeutics RVNC:US $ 10.66M 0.5M
Supernus Pharmaceuticals SUPN:US $ 88.8M 2.84M
Teva Pharmaceutical Industries TEVA:US $ 4012M 194M